Remove Government Remove Immune Response Remove Trials
article thumbnail

Moderna says its COVID-19 vaccine shows promise in elderly patients

The Pharma Data

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Earlier this month, the US Government announced that it would purchase 100 million doses of the Moderna vaccine in a deal worth $1.53

Vaccine 90
article thumbnail

Medicago Says COVID-19 Vaccine Candidate Triggers Promising Immune Response | 2020-11-10

The Pharma Data

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Based on the promising phase 1 data, the company plans to proceed with a phase 2/3 clinical trial. “We

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Vaccine Development Landscape and Its Associated Challenges

DrugBank

Adjuvants are substances added to vaccines to enhance the immune response. They work by decreasing the solubility of the vaccine, which sustains the release of the drug and prolongs the immune response. Even after a vaccine is approved and distributed, the pharmaceutical industry's responsibility does not end.

Vaccine 79
article thumbnail

COVID19: Serology is harder than it looks

DrugBaron

If enough people have become immune, and critically can neither suffer symptoms nor act as a carrier for the virus, then immunity will replace social distancing as the key breaker of transmission chains. The solution is a test for the immune response to the virus (often called a “serology test”).

article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. Source link.

article thumbnail

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 is being evaluated in an ongoing Phase 3 trial in the U.K. and Australia. About Matrix-M.

Vaccine 52
article thumbnail

Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council

The Pharma Data

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. This Phase IIa trial follows a preliminary study conducted by Prof.